{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:24:51Z","timestamp":1787869491877,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.juro.2010.09.086","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T04:14:58Z","timestamp":1292645698000},"page":"439-444","source":"Crossref","is-referenced-by-count":95,"title":["Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1097","volume":"185","author":[{"given":"Jose A.","family":"Karam","sequence":"first","affiliation":[{"name":"Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Varella","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Taussig Cancer Institute, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.09.086_bib1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0022-5347(05)65640-6","article-title":"The changing natural history of renal cell carcinoma","volume":"166","author":"Pantuck","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib2","doi-asserted-by":"crossref","first-page":"6335S","DOI":"10.1158\/1078-0432.CCR-sup-040026","article-title":"Debulking nephrectomy in metastatic renal cancer","volume":"10","author":"Flanigan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.09.086_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.09.086_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.09.086_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2010.09.086_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2010.09.086_bib7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2010.09.086_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1464-410X.2009.08490.x","article-title":"Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma","volume":"104","author":"Daliani","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.09.086_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.juro.2008.05.006","article-title":"Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma","volume":"180","author":"Eggener","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib10","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/archsurg.1992.01420110091018","article-title":"Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission","volume":"127","author":"Kim","year":"1992","journal-title":"Arch Surg"},{"key":"10.1016\/j.juro.2010.09.086_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0090-4295(98)00033-8","article-title":"Efficacy of multimodality therapy in advanced renal cell carcinoma","volume":"51","author":"Krishnamurthi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.juro.2010.09.086_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0003-4975(92)91136-W","article-title":"Renal cell carcinoma: resection of solitary and multiple metastases","volume":"54","author":"Pogrebniak","year":"1992","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.juro.2010.09.086_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-5347(17)35986-4","article-title":"Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma","volume":"149","author":"Sella","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib14","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/1097-0142(19920401)69:7<1850::AID-CNCR2820690729>3.0.CO;2-I","article-title":"Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy","volume":"69","author":"Sherry","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2010.09.086_bib15","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0022-5347(01)65454-5","article-title":"Renal cell carcinoma metastatic to the lung: potential benefit in the combination of biological therapy and surgery","volume":"156","author":"Tanguay","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CGC.2006.n.042","article-title":"Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases","volume":"5","author":"Rini","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.juro.2010.09.086_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib18","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2010.09.086_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.juro.2008.10.001","article-title":"Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma","volume":"181","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.juro.2008.03.047","article-title":"Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma","volume":"180","author":"Margulis","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib22","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2008.21.3660","article-title":"Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma","volume":"27","author":"Jonasch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2009.24.7759","article-title":"Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma","volume":"28","author":"Cowey","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.juro.2009.05.014","article-title":"Surgical resection of renal cell carcinoma after targeted therapy","volume":"182","author":"Thomas","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.09.086_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1464-410X.2008.07660.x","article-title":"Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm","volume":"102","author":"Shuch","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.09.086_bib26","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib27","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.09.086_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(09)70341-9","article-title":"Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care","volume":"11","author":"Bose","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710047191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710047191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.09.086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:45:08Z","timestamp":1651182308000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.09.086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1016\/j.juro.2010.09.086"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.09.086","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.7577956.9593059","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.7577956.7876054","asserted-by":"object"}]},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}